Ground Report | New Delhi: Covaxin 77% effective against Covid; Bharat Biotech’s Covid Vaccine – Covaxin was found to be 77.8 percent effective against Covid-19. Lancet peer-reviewed that this analysis was based on 130 covid cases with symptoms. According to data from phase-three clinical trials, Covaxin exhibits 77.8 percent efficacy against symptomatic COVID-19.
Covaxin 77% effective against Covid
The official statement released by Bharat Biotech, citing the study conducted by Lancet, said, “Covaxin is the only COVID-19 vaccine that has demonstrated 65.2 percent efficacy data from Phase III clinical trials against the delta variant.”
Meanwhile, data from Phase III clinical trials show that the vaccine has an efficacy of 65.2 percent compared to the delta version. The vaccine elicits a strong antibody response two weeks after two doses of Covaxin, the Lancet said in a statement.
ALSO READ: COVID-19: How to test for Covid-19 at home
The Journal said no vaccine-related deaths or any serious adverse events were recorded during the trial. The Journal further noted that most adverse events, including injection site pain, headache, fatigue, fever, were mild and occurred within seven days of the vaccine. This study regarding covaccine comes a week after it was approved by the World Health Organization (WHO).
“Efficacy analysis shows that Covaxin is 77.8 percent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, 24 in the vaccine group versus 106 in the placebo group,” the company statement said. Has been observed.” Further, it said that Covaxin would be 93.4 percent effective against severe symptomatic COVID-19.
development and clinical trials
“Safety analysis shows that reported adverse events were similar to placebo, with 12 percent of subjects experiencing commonly known side effects and less than 0.5 percent of subjects experiencing serious adverse events,” it said. “Efficacy data shows 63.6 percent protection against asymptomatic COVID-19, 65.2 percent protection against SARS-CoV-2, B.1.617.2 delta, and 70.8 percent protection against all forms of SARS-CoV-2 virus,” India Biotech added.
Dr Krishna Ella, Chairman and Managing Director (CMD), Bharat Biotech, said, “Data from our product development and clinical trials have been published in 10 peer-reviewed journals, making Covaxin the most published COVID-fighting medicine in the world. One of the 19 vaccines in the world,” he said.
ALSO READ: Covid-19 vaccination for children
“I am delighted to see that the efficacy data from Phase III has also been published in The Lancet. This in itself says a lot about Covaxin strong position among other leading COVID-19 vaccines in the world, ”Dr Balram Bhargava, Director General, Indian Council for Medical Research (ICMR) said.
“Covaxin’s journey from bench to bedside in less than 10 months shows the immense strength of ‘Atmanirbhar Bharat’ as well as Indian universities and industry in fighting against all odds and carving out a place in the global community”, added Bhargava. Recently, the World Health Organization granted Covaxin an emergency use list allowing countries to speed up their regulatory approval to import and administer doses.